New drug duo aims to shrink breast tumors before surgery
NCT ID NCT07393425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two targeted drugs (trastuzumab deruxtecan and pertuzumab) can shrink or eliminate HER2-positive breast tumors before surgery. About 50 women with stage II-III breast cancer will receive the drugs for three cycles. If the tumor responds well, they continue the same treatment; if not, they switch to a standard chemotherapy regimen. The goal is to see how many patients have no cancer left at the time of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can an oral chemo pill boost breast cancer treatment?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Blood test may reveal if breast cancer treatment is working
- New vaccine combo aims to supercharge immune attack on breast cancer
- New study tests targeted pill combo for advanced breast cancer in Real-World settings